Key result
Accelerated atherosclerosis in systemic lupus erythematosus is driven by traditional and disease-specific risk factors, with hydroxychloroquine showing cardioprotective effects while statins do not.
In patients with SLE, traditional and disease-specific risk factors drive accelerated atherosclerosis; while statins lack proven cardiovascular benefit, hydroxychloroquine appears cardioprotective.
No takes yet. Share an insight, caveat, or question.
May support hydroxychloroquine for CV protection in SLE; leaves open statin efficacy and requires prospective validation.
Stojan et al. (2013) conducted a review in Systemic lupus erythematosus (SLE) and atherosclerosis. Accelerated atherosclerosis in systemic lupus erythematosus is driven by traditional and disease-specific risk factors, with hydroxychloroquine showing cardioprotective effects while statins do not.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: